Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® ...
MPR12h
Semaglutide Improves Walking Ability in T2D Patients With Peripheral Artery Disease
Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...
Clinical trial shows oral semaglutide vastly reduces heart attacks, strokes in people with type 2 diabetes
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
BioSpace15h
Novo Paints ‘Complicated’ Cardio Picture for Semaglutide Franchise
According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...
Why won’t my doctor prescribe Ozempic for weight loss?
Ask a Doctor is new series of physician-authored columns offering insights and advice on common health topics. It is not a ...
News-Medical.Net23h
New trial shows oral semaglutide reduces cardiovascular events in diabetes patients
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...